COMPUGEN Top Management

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>CO</div>
CGEN -- Israel Stock  

ILA 4,802  273.00  5.38%

COMPUGEN employes about 61 people. The company is managed by 18 executives with total tenure of roughly 118 years, averaging almost 6.0 years of service per executive having 3.39 employees per reported executive. Analysis of COMPUGEN management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with COMPUGEN future performance. Continue to Trending Equities.

Search Insiders

  Anat CohenDayag  CEO
President, Chief Executive Officer, Director
  Paul Sekhri  Chairman
Chairman of the Board
  Martin Gerstel  Chairman
Chairman of the Board

COMPUGEN Management Team Effectiveness

COMPUGEN has return on total asset (ROA) of (0.5516) % which means that it has lost $0.5516 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (78.0668) % meaning that it generated substantial loss on money invested by shareholders. COMPUGEN management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. As of June 2, 2020, Return on Investment is expected to decline to -86.62. The current year Return on Average Assets is expected to grow to -0.0055COMPUGEN Total Assets are expected to significantly increase based on the last few years of reporting. The last year's Total Assets were at 53.76 Million. The current year Current Assets is expected to grow to about 91 M, whereas Return on Average Assets are expected to grow to (0.0055) . The current year Current Liabilities is expected to grow to about 6.9 M, whereas Total Liabilities is expected to decline to about 13.2 M. As of June 2, 2020, Weighted Average Shares is expected to decline to about 62.4 M. In addition to that, Weighted Average Shares Diluted is expected to decline to about 53 M

COMPUGEN Workforce Comparison

COMPUGEN is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 122. COMPUGEN totals roughly 61.0 in number of employees claiming about 50% of stocks in Biotechnology industry.

COMPUGEN Stakeholders

Anat CohenDayag President, Chief Executive Officer, Director
Paul Sekhri Chairman of the Board
Martin Gerstel Chairman of the Board
Zurit Levine Vice President - Research and Discovery
Ari Krashin Chief Financial Officer
Joshua Shemer Independent External Director
Michal Preminger Director
Dov Hershberg Director
Arie Ovadia Independent External Director
Eran Perry Director
Sanford Zweifach Director
Gilead Halevy Director
Ruth Arnon Independent Director
Kinneret Savitsky Director
Yair Aharonowitz Independent External Director
JeanPierre Bizzari Director
John Hunter VP of Antibody RandD and Site Head of Compugen USA Inc
Henry Adewoye Chief Medical Officer

COMPUGEN Manpower Efficiency

Return on COMPUGEN Manpower

Revenue Per Employee194.2 K
Revenue Per Executive36.5 K
Net Loss Per Employee483.5 K
Net Loss Per Executive1.7 M
Working Capital Per Employee1.4 M
Working Capital Per Executive4.7 M

Per Employee

COMPUGEN Per Employee Growth Over Time

  Net Income Per Employee

  Revenue Per Employee

 2016 2017 2019 2020 (projected)
Receivables Turnover0.137808177.11159.4171.98
PPandE Turnover0.1184124.444.03.18
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 61 people.
Continue to Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page